Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinnervate Partners with Oncotest and SBH Sciences

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.

Reinnervate Ltd today announced partnerships with two oncology-focussed CRO‟s to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models. 

The introductory service ranges in price from $1,499 to $2,499 and has the following experimental outline: 

• Client picks two cancer cell lines from the available panel (over 200 tumour cell lines are available)
• Client provides up to 2 test compounds or specifies two commercially available drugs to be used
• CROs include one positive control cell line and one positive control compound
• All 3 compounds are tested on the specified 3D tumour cells cultured in Alvetex® 96 3D cell culture plates
• A dose response experiment with ten concentrations in duplicates will be performed using the Promega Cell Titer-Glo® assay
• CRO provides a comprehensive data report with IC50 values and a follow-up telephone conference
• Comparison of 2D and 3D tumour cell responses can be provided (depending on service chosen) 

"These new introductory 3D tumour cell services will allow more scientists to explore the differences in drug response between 2D and 3D cultured tumour cells‟ said Richard Rowling, Commercial Director at Reinnervate Ltd. "These services have been priced at a level which should be affordable for most groups that have not yet had the time to explore the improved biological relevance offered by 3D cell culture systems‟ he added. 

Torsten Giesemann, Department Head at Oncotest commented, „We have been using Alvetex® 96 3D cell culture plates for some time now and are keen to help as many clients as possible explore the potential benefits of testing new oncology drugs on 3D tumour cells cultured in a 3D format. There is an increasing body of scientific data showing that tumour cells cultured as monolayers are a poor proxy for the in vivo situation.‟ 

SBH Sciences CEO, Raphael Nir said, „We have a panel of over 200 different tumour cell lines and look forward to helping our clients evaluate 3D tumour cell screening and compare the differences in drug response between 2D and 3D cell culture systems using Alvetex® technology‟.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!